ALM201   Click here for help

GtoPdb Ligand ID: 11485

Comment: ALM201 is a small 23 amino acid peptide that is derived from the FK506 binding protein FKBPL. It has anti-angiogenic and anti-tumour activities [2].
1. Almac Discovery. 
ALM201 – Orphan Drug Designation Granted in Ovarian Cancer.
Accessed on 17/03/2021. Modified on 17/03/2021.,
2. Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I et al.. (2020)
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Br J Cancer, 122 (3): 361-371. [PMID:31772325]
3. McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A et al.. (2019)
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
BMC Cancer, 19 (1): 351. [PMID:30975104]
4. McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A et al.. (2013)
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
Clin Cancer Res, 19 (14): 3881-93. [PMID:23741069]
5. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H et al.. (2011)
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Clin Cancer Res, 17 (5): 1044-56. [PMID:21364036]